Allergan Stock Price, News & Analysis (NYSE:AGN)

$181.33 1.69 (0.94 %)
(As of 01/22/2018 01:22 AM ET)
Previous Close$179.64
Today's Range$179.12 - $181.97
52-Week Range$160.07 - $256.80
Volume4.04 million shs
Average Volume2.65 million shs
Market Capitalization$60.31 billion
P/E Ratio-8.03
Dividend Yield1.56%
Beta1.11

About Allergan (NYSE:AGN)

Allergan logoAllergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drugs - Generic
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:AGN
CUSIP01849010
Phone353-1435-7700

Debt

Debt-to-Equity Ratio0.40%
Current Ratio1.18%
Quick Ratio1.08%

Price-To-Earnings

Trailing P/E Ratio-8.02700309871625
Forward P/E Ratio11.15
P/E Growth1.33

Sales & Book Value

Annual Sales$14.57 billion
Price / Sales4.14
Cash Flow$32.55 per share
Price / Cash5.57
Book Value$190.01 per share
Price / Book0.95

Profitability

Trailing EPS($22.59)
Net Income$14.97 billion
Net Margins-47.27%
Return on Equity8.00%
Return on Assets4.45%

Miscellaneous

Employees16,700
Outstanding Shares332,580,000

Allergan (NYSE:AGN) Frequently Asked Questions

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan announced a quarterly dividend on Friday, October 27th. Shareholders of record on Friday, November 17th will be paid a dividend of $0.70 per share on Friday, December 15th. This represents a $2.80 annualized dividend and a yield of 1.54%. The ex-dividend date of this dividend is Thursday, November 16th. View Allergan's Dividend History.

How will Allergan's stock buyback program work?

Allergan declared that its Board of Directors has authorized a share repurchase program on Tuesday, September 26th 2017, which allows the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's board of directors believes its stock is undervalued.

How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) issued its earnings results on Wednesday, November, 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.06 by $0.09. The firm had revenue of $4.03 billion for the quarter, compared to analysts' expectations of $4.04 billion. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The company's quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.32 EPS. View Allergan's Earnings History.

When will Allergan make its next earnings announcement?

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, February, 6th 2018. View Earnings Estimates for Allergan.

What guidance has Allergan issued on next quarter's earnings?

Allergan issued an update on its FY18 earnings guidance on Monday, January, 8th. The company provided earnings per share (EPS) guidance of ≥$15.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.85. The company issued revenue guidance of ~$15.0-15.3 billion, compared to the consensus revenue estimate of $15.65 billion.

Where is Allergan's stock going? Where will Allergan's stock price be in 2018?

17 analysts have issued 12 month price objectives for Allergan's stock. Their predictions range from $160.07 to $280.00. On average, they anticipate Allergan's stock price to reach $225.60 in the next twelve months. View Analyst Ratings for Allergan.

What are Wall Street analysts saying about Allergan stock?

Here are some recent quotes from research analysts about Allergan stock:

  • 1. According to Zacks Investment Research, "Allergan’s products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar support sales. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, while we remain optimistic about the company’s growth prospects, it is facing potential loss of exclusivity for many products in 2018 including Namenda XR and Restasis. In October 2017, a Texas federal district court invalidated four of the six patents covering Restasis, potentially opening doors for early generic competition. Though Restasis patents are scheduled to expire in August 2024, a generic version may be launched as early as mid-2018. Also, new competition for key growth drivers, Restasis and Linzess, is an investor concern. Allergan’s shares underperformed the industry in the past six months. " (1/2/2018)
  • 2. Cantor Fitzgerald analysts commented, "Allergan announced mixed top-line results from its Phase 2b study of CVC for NASH. The Street was waiting for this, and the delay relative to Street expectations had been one reason the stock has been weak." (9/22/2017)
  • 3. Leerink Swann analysts commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic franchises we're modestly raising our sales and EPS estimates." (2/9/2017)

Who are some of Allergan's key competitors?

Who owns Allergan stock?

Allergan's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.36%), Factory Mutual Insurance Co. (0.19%), Intermede Investment Partners Ltd (0.12%), Confluence Investment Management LLC (0.10%), Gateway Investment Advisers LLC (0.07%) and Cacti Asset Management LLC (0.07%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Maria Teresa Hilado, Nesli Basgoz, Paul Bisaro and William Meury. View Institutional Ownership Trends for Allergan.

Who sold Allergan stock? Who is selling Allergan stock?

Allergan's stock was sold by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC, Gillespie Robinson & Grimm Inc., Pennsylvania Trust Co, Sit Investment Associates Inc., Berson & Corrado Investment Advisors LLC, Gibraltar Capital Management Inc., Gofen & Glossberg LLC IL and Appleton Partners Inc. MA. Company insiders that have sold Allergan company stock in the last year include Nesli Basgoz, Paul Bisaro and William Meury. View Insider Buying and Selling for Allergan.

Who bought Allergan stock? Who is buying Allergan stock?

Allergan's stock was bought by a variety of institutional investors in the last quarter, including Intermede Investment Partners Ltd, Clark Estates Inc. NY, Schwab Charles Investment Management Inc., Factory Mutual Insurance Co., State of Alaska Department of Revenue, Confluence Investment Management LLC, Hikari Power Ltd and Fox Run Management L.L.C.. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin and Maria Teresa Hilado. View Insider Buying and Selling for Allergan.

How do I buy Allergan stock?

Shares of Allergan can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allergan's stock price today?

One share of Allergan stock can currently be purchased for approximately $181.33.

How big of a company is Allergan?

Allergan has a market capitalization of $60.31 billion and generates $14.57 billion in revenue each year. The company earns $14.97 billion in net income (profit) each year or ($22.59) on an earnings per share basis. Allergan employs 16,700 workers across the globe.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 353-1435-7700 or via email at [email protected]


MarketBeat Community Rating for Allergan (AGN)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  938 (Vote Outperform)
Underperform Votes:  418 (Vote Underperform)
Total Votes:  1,356
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Allergan (NYSE:AGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.592.612.582.71
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $225.60$233.00$251.76$275.88
Price Target Upside: 29.83% upside36.33% upside33.72% upside11.96% upside

Allergan (NYSE:AGN) Consensus Price Target History

Price Target History for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/9/2018Deutsche BankReiterated RatingBuy$215.00MediumView Rating Details
1/9/2018CitigroupLower Price TargetBuy$215.00N/AView Rating Details
1/5/2018Wells Fargo & CoSet Price TargetBuy$245.00LowView Rating Details
1/4/2018Royal Bank of CanadaSet Price TargetBuy$218.00LowView Rating Details
12/19/2017Credit Suisse GroupSet Price TargetBuy$224.00 -> $214.00LowView Rating Details
12/12/2017Cantor FitzgeraldSet Price TargetHold$191.00LowView Rating Details
12/7/2017ArgusDowngradeBuy -> Hold$256.80 -> $160.07LowView Rating Details
12/6/2017Morgan StanleySet Price TargetBuy$200.00MediumView Rating Details
11/27/2017Leerink SwannReiterated RatingOutperform -> Outperform$237.00LowView Rating Details
10/22/2017JPMorgan Chase & Co.Set Price TargetBuy$275.00N/AView Rating Details
10/20/2017CowenSet Price TargetBuy$400.00 -> $280.00N/AView Rating Details
10/19/2017MizuhoDowngradeBuy -> Neutral$193.00 -> $193.00N/AView Rating Details
10/18/2017Edward JonesReiterated RatingBuy -> HoldN/AView Rating Details
10/18/2017Sanford C. BernsteinSet Price TargetBuy$296.00 -> $252.00N/AView Rating Details
10/13/2017Piper Jaffray CompaniesSet Price TargetHold$227.00N/AView Rating Details
10/2/2017BarclaysReiterated RatingEqual WeightLowView Rating Details
5/10/2017Goldman Sachs GroupDowngradeBuy -> Neutral$262.00HighView Rating Details
12/23/2016Bank of AmericaReiterated RatingBuy$280.00N/AView Rating Details
11/21/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
4/18/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
4/7/2016Raymond James FinancialLower Price TargetOutperform$317.00 -> $275.00N/AView Rating Details
4/7/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
4/7/2016Susquehanna BancsharesDowngradePositive -> Neutral$345.00 -> $275.00N/AView Rating Details
4/5/2016NomuraReiterated RatingBuy$350.00 -> $330.00N/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

Allergan (NYSE:AGN) Earnings History and Estimates Chart

Earnings by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE AGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/6/2018$4.73N/AView Earnings Details
11/1/2017Q3 2017$4.06$4.15$4.04 billion$4.03 billionViewN/AView Earnings Details
8/3/2017Q2 2017$3.95$4.02$3.95 billion$4.01 billionViewListenView Earnings Details
5/9/2017Q1 2017$3.32$3.35$3.53 billion$3.57 billionViewListenView Earnings Details
2/8/2017Q416$3.76$3.90$3.77 billion$3.86 billionViewListenView Earnings Details
11/2/2016Q316$3.57$3.32$3.73 billion$3.62 billionViewListenView Earnings Details
8/8/2016Q216$3.34$3.35$4.10 billion$3.68 billionViewListenView Earnings Details
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details
11/4/2015Q315$3.20$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details
8/6/2015Q215$4.41$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details
5/11/2015Q115$3.84$4.30$4.04 billion$4.23 billionViewListenView Earnings Details
2/18/2015Q414$3.67$3.91$3.84 billion$4.01 billionViewN/AView Earnings Details
11/5/2014Q414$1.83$2.17$1.90 billion$1.91 billionViewN/AView Earnings Details
11/5/2014Q314$3.10$3.19$3.63 billion$3.68 billionViewN/AView Earnings Details
8/5/2014Q314$1.76$1.78$1.78 billion$1.79 billionViewListenView Earnings Details
8/5/2014Q214$3.36$3.42$2.55 billion$2.67 billionViewN/AView Earnings Details
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details
4/30/2014Q114$1.13$1.18$1.60 billion$1.65 billionViewN/AView Earnings Details
4/30/2014Q114$3.23$3.49$2.59 billion$2.66 billionViewListenView Earnings Details
2/20/2014Q413$3.05$3.17$2.68 billion$2.78 billionViewListenView Earnings Details
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details
10/29/2013Q313$2.09$2.09$2.04 billion$2.01 billionViewListenView Earnings Details
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.60 billionViewN/AView Earnings Details
7/25/2013Q2 2013$2.00$2.01$1.99 billion$1.99 billionViewListenView Earnings Details
5/2/2013Q1 2013$1.86$1.99$1.97 billion$1.90 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details
2/19/2013Q4 2012$1.53$1.59$1.74 million$1.75 billionViewListenView Earnings Details
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details
8/1/2012$1.06$1.07ViewN/AView Earnings Details
5/2/2012$0.87$0.86ViewN/AView Earnings Details
2/14/2012Q4 2011$1.75$1.77ViewN/AView Earnings Details
2/2/2012$1.00$1.00ViewN/AView Earnings Details
10/26/2011$0.90$0.92ViewN/AView Earnings Details
8/3/2011$0.95$0.96ViewN/AView Earnings Details
7/26/2011Q2 2011$1.00$1.01ViewN/AView Earnings Details
5/4/2011$0.74$0.77ViewN/AView Earnings Details
2/15/2011Q4 2010$0.93$0.93ViewN/AView Earnings Details
2/2/2011$0.89$0.88ViewN/AView Earnings Details
11/4/2010Q3 2010$0.84$0.85ViewN/AView Earnings Details
8/5/2010Q2 2010$0.81$0.83ViewN/AView Earnings Details
5/10/2010Q1 2010$0.74$0.63ViewN/AView Earnings Details
2/23/2010Q4 2009$0.72$0.85ViewN/AView Earnings Details
11/4/2009Q3 2009$0.65$0.66ViewN/AView Earnings Details
7/29/2009Q2 2009$0.57$0.61ViewN/AView Earnings Details
4/30/2009Q1 2009$0.49$0.58ViewN/AView Earnings Details
2/19/2009Q4 2008$0.50$0.53ViewN/AView Earnings Details
10/29/2008Q3 2008$0.46$0.48ViewN/AView Earnings Details
8/6/2008Q2 2008$0.48$0.48ViewN/AView Earnings Details
5/1/2008Q1 2008$0.51$0.55ViewN/AView Earnings Details
2/20/2008Q4 2007$0.31$0.35ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Allergan (NYSE:AGN) Earnings Estimates

2018 EPS Consensus Estimate: $15.36
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$3.73$3.73$3.73
Q2 20181$3.79$3.79$3.79
Q3 20181$3.78$3.78$3.78
Q4 20181$4.06$4.06$4.06
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Allergan (NYSE:AGN) Dividend Information

Most Recent Dividend:12/15/2017
Annual Dividend:$2.80
Dividend Yield:1.54%
Dividend Growth:141.00% (3 Year Average)
Payout Ratio:-12.39% (Trailing 12 Months of Earnings)
17.21% (Based on This Year's Estimates)
18.11% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/27/2017quarterly$0.701.58%11/16/201711/17/201712/15/2017
8/2/2017Quarterly$0.701.12%8/16/20178/18/20179/15/2017
5/5/2017quarterly$0.700.01%5/16/20175/18/20176/15/2017
11/2/2016quarterly$0.702/24/20172/28/20173/28/2017
2/4/2015quarterly$0.050.09%2/5/20152/9/20153/20/2015
10/27/2014quarterly$0.0511/20/201412/11/2014
7/28/2014quarterly$0.050.12%8/13/20148/15/20149/5/2014
5/7/2014quarterly$0.050.12%5/21/20145/23/20146/13/2014
2/5/2014quarterly$0.050.17%2/26/20142/28/20143/21/2014
10/30/2013quarterly$0.050.22%11/18/201311/20/201312/11/2013
7/31/2013quarterly$0.050.22%8/20/20138/22/20139/12/2013
5/2/2013quarterly$0.050.2%5/21/20135/23/20136/13/2013
2/6/2013quarterly$0.050.18%2/26/20132/28/20133/21/2013
(Data available from 1/1/2013 forward)

Insider Trades

Allergan (NYSE AGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.36%
Institutional Ownership Percentage: 81.26%
Insider Trades by Quarter for Allergan (NYSE:AGN)
Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE AGN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/7/2017Chris W. BodineDirectorBuy3,030$164.77$499,253.10View SEC Filing  
12/6/2017Brent L. SaundersChairmanBuy4,600$164.74$757,804.00View SEC Filing  
12/5/2017Christopher J. CoughlinDirectorBuy10,000$163.30$1,633,000.00View SEC Filing  
12/1/2017William MeuryInsiderSell11,807$173.89$2,053,119.23View SEC Filing  
5/18/2017Nesli BasgozDirectorSell1,889$220.45$416,430.05View SEC Filing  
3/2/2017Paul BisaroDirectorSell70,000$246.68$17,267,600.00274,226View SEC Filing  
12/8/2016Nesli BasgozDirectorSell500$188.72$94,360.00View SEC Filing  
11/21/2016Brent L. SaundersCEOBuy5,250$189.13$992,932.50View SEC Filing  
11/11/2016Maria Teresa HiladoCFOBuy1,422$210.64$299,530.0812,659View SEC Filing  
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.7711,957View SEC Filing  
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.905,242View SEC Filing  
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.004,062View SEC Filing  
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00421,755View SEC Filing  
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00132,862View SEC Filing  
6/9/2015Nesli BasgozDirectorSell2,200$297.89$655,358.00View SEC Filing  
11/26/2014William MeuryInsiderSell4,550$269.14$1,224,587.00View SEC Filing  
9/8/2014Albert Paonessa IIIInsiderSell6,642$230.49$1,530,914.58View SEC Filing  
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.008,223View SEC Filing  
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.0012,723View SEC Filing  
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.0011,600View SEC Filing  
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.0016,591View SEC Filing  
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.006,401View SEC Filing  
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.748,220View SEC Filing  
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.0017,327View SEC Filing  
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.0017,327View SEC Filing  
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.007,142View SEC Filing  
9/16/2013Albert HummelDirectorSell6,200$137.81$854,422.0082,776View SEC Filing  
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.008,142View SEC Filing  
9/4/2013George Fred WilkinsonInsiderSell16,749$138.00$2,311,362.00View SEC Filing  
9/4/2013Jack MichelsonDirectorSell6,064$139.54$846,170.56View SEC Filing  
8/29/2013David BuchenInsiderSell10,000$135.56$1,355,600.0097,373View SEC Filing  
8/26/2013Albert HummelDirectorSell40,000$134.44$5,377,600.0092,776View SEC Filing  
8/20/2013Paul BisaroCEOSell50,000$135.30$6,765,000.00469,232View SEC Filing  
8/15/2013Albert Paonessa IIIInsiderSell5,476$135.89$744,133.6433,812View SEC Filing  
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.009,142View SEC Filing  
8/14/2013R Todd JoyceCFOSell15,000$137.98$2,069,700.0080,470View SEC Filing  
8/13/2013Albert HummelDirectorSell10,000$133.85$1,338,500.00132,776View SEC Filing  
8/12/2013Cathy KlemaDirectorSell1,667$133.03$221,761.0119,608View SEC Filing  
8/12/2013David BuchenInsiderSell17,000$133.03$2,261,510.0097,373View SEC Filing  
8/9/2013Ronald TaylorDirectorSell5,000$135.14$675,700.0027,942View SEC Filing  
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.0016,871View SEC Filing  
8/5/2013Charles EbertVPSell8,244$136.25$1,123,245.0019,970View SEC Filing  
8/5/2013Michel FeldmanDirectorSell10,000$136.94$1,369,400.0012,941View SEC Filing  
8/2/2013Robert StewartInsiderSell14,564$136.02$1,980,995.2873,891View SEC Filing  
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  
3/14/2013Charles M MayrInsiderSell1,000$91.77$91,770.00View SEC Filing  
3/12/2013Michael J FedidaDirectorSell8,000$89.00$712,000.00View SEC Filing  
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Allergan (NYSE AGN) News Headlines

Source:
DateHeadline
Amgen/Allergan's Avastin Biosimilar Secures EU ApprovalAmgen/Allergan's Avastin Biosimilar Secures EU Approval
finance.yahoo.com - January 19 at 12:19 PM
Amgen (AMGN) and Allergans (AGN) MVASI For Treatment Of Certain Types Of Cancer Approved by ECAmgen (AMGN) and Allergan's (AGN) MVASI For Treatment Of Certain Types Of Cancer Approved by EC
www.streetinsider.com - January 19 at 8:50 AM
Amgen (AMGN) and Allergans (AGN) MVASI For Treatment Of Certain Types Of Cancer Approved by EC - StreetInsider.comAmgen (AMGN) and Allergan's (AGN) MVASI For Treatment Of Certain Types Of Cancer Approved by EC - StreetInsider.com
www.streetinsider.com - January 19 at 7:44 AM
See what the IHS Markit Score report has to say about Allergan plc.See what the IHS Markit Score report has to say about Allergan plc.
finance.yahoo.com - January 18 at 11:50 AM
Allergan Could Raise $1 Billion From Anti-Infectives Sale - RBC Capital Markets - TheStreet.comAllergan Could Raise $1 Billion From Anti-Infectives Sale - RBC Capital Markets - TheStreet.com
www.thestreet.com - January 18 at 6:55 AM
Allergan Could Raise $1 Billion From Anti-Infectives Sale - RBC Capital MarketsAllergan Could Raise $1 Billion From Anti-Infectives Sale - RBC Capital Markets
finance.yahoo.com - January 18 at 6:55 AM
Allergan: Insiders Buy; Investors Shy Away - Seeking AlphaAllergan: Insiders Buy; Investors Shy Away - Seeking Alpha
seekingalpha.com - January 17 at 3:19 PM
Allergan Needs More Time to Make a Proper BottomAllergan Needs More Time to Make a Proper Bottom
finance.yahoo.com - January 17 at 3:19 PM
Polaris Global Value Fund 4th Quarter Shareholder LetterPolaris Global Value Fund 4th Quarter Shareholder Letter
finance.yahoo.com - January 17 at 3:19 PM
Judge approves settlement between Allergan shareholders and AckmanJudge approves settlement between Allergan shareholders and Ackman
www.bizjournals.com - January 17 at 11:38 AM
Imprimis receives FDA warning over eye medication advertisingImprimis receives FDA warning over eye medication advertising
finance.yahoo.com - January 17 at 10:37 AM
Ironwood Pharma (IRWD), Allergan (AGN) Settle with Sun Pharma Resolving LINZESS Patent LitigationIronwood Pharma (IRWD), Allergan (AGN) Settle with Sun Pharma Resolving LINZESS Patent Litigation
www.streetinsider.com - January 16 at 3:18 PM
Teva's Trisenox Gets FDA Approval as First-Line TreatmentTeva's Trisenox Gets FDA Approval as First-Line Treatment
finance.yahoo.com - January 16 at 10:43 AM
Gabelli Weighs in on Allergan plcs FY2021 Earnings (AGN)Gabelli Weighs in on Allergan plc's FY2021 Earnings (AGN)
www.americanbankingnews.com - January 15 at 4:16 PM
$4.28 Billion in Sales Expected for Allergan plc (AGN) This Quarter$4.28 Billion in Sales Expected for Allergan plc (AGN) This Quarter
www.americanbankingnews.com - January 15 at 3:00 AM
Zacks: Analysts Expect Allergan plc (AGN) Will Post Earnings of $4.73 Per ShareZacks: Analysts Expect Allergan plc (AGN) Will Post Earnings of $4.73 Per Share
www.americanbankingnews.com - January 13 at 9:34 PM
1st trial date set in state lawsuit over opioid epidemic1st trial date set in state lawsuit over opioid epidemic
marketbeat.com - January 12 at 4:03 PM
Allergan plc Forecasted to Earn FY2018 Earnings of $15.95 Per Share (AGN)Allergan plc Forecasted to Earn FY2018 Earnings of $15.95 Per Share (AGN)
www.americanbankingnews.com - January 12 at 3:42 PM
Concerns About Allergans Health Are OverblownConcerns About Allergan's Health Are Overblown
finance.yahoo.com - January 12 at 10:44 AM
Ackman’s Pershing Square cuts hedge-fund fees due to lawsuit settlementAckman’s Pershing Square cuts hedge-fund fees due to lawsuit settlement
finance.yahoo.com - January 11 at 3:19 PM
Pershing Square lowering management feesPershing Square lowering management fees
finance.yahoo.com - January 11 at 3:19 PM
3 Reasons Allergan Is Set Up for Success in 20183 Reasons Allergan Is Set Up for Success in 2018
finance.yahoo.com - January 10 at 3:20 PM
Leerink Swann Comments on Allergan plcs Q1 2018 Earnings (AGN)Leerink Swann Comments on Allergan plc's Q1 2018 Earnings (AGN)
www.americanbankingnews.com - January 10 at 9:38 AM
Judge urges action on 100 percent manmade opioid crisisJudge urges action on '100 percent manmade' opioid crisis
finance.yahoo.com - January 9 at 4:16 PM
Allergan CEO Saunders on the company's booming Botox busi...Allergan CEO Saunders on the company's booming Botox busi...
finance.yahoo.com - January 9 at 3:21 PM
Allergan plc (NYSE:AGN): What Does The Future Look Like?Allergan plc (NYSE:AGN): What Does The Future Look Like?
finance.yahoo.com - January 9 at 3:21 PM
Allergan's (AGN) Sales Guidance for 2018 Lower Than ExpectedAllergan's (AGN) Sales Guidance for 2018 Lower Than Expected
finance.yahoo.com - January 9 at 3:21 PM
Allergans (AGN) Sales Guidance for 2018 Lower Than Expected - NasdaqAllergan's (AGN) Sales Guidance for 2018 Lower Than Expected - Nasdaq
www.nasdaq.com - January 9 at 3:18 PM
3 Stocks to Watch on Tuesday: A Schulman Inc, Allergan plc and Urban Outfitters, Inc. - Investorplace.com3 Stocks to Watch on Tuesday: A Schulman Inc, Allergan plc and Urban Outfitters, Inc. - Investorplace.com
investorplace.com - January 9 at 3:18 PM
Evolus readies IPO - Seeking AlphaEvolus readies IPO - Seeking Alpha
seekingalpha.com - January 9 at 3:18 PM
U.S. pharma executives expect deals to pick up after tax overhaulU.S. pharma executives expect deals to pick up after tax overhaul
finance.yahoo.com - January 9 at 3:18 PM
Cramer's Stop Trading: Allergan's 'salami strategy'Cramer's Stop Trading: Allergan's 'salami strategy'
finance.yahoo.com - January 9 at 10:34 AM
Stocks making the biggest moves premarket: TGT, AMZN, UAA, PYPL & moreStocks making the biggest moves premarket: TGT, AMZN, UAA, PYPL & more
finance.yahoo.com - January 9 at 10:34 AM
Allergan (AGN) Prelim. FY18 Guidance Misses Views - StreetInsider.comAllergan (AGN) Prelim. FY18 Guidance Misses Views - StreetInsider.com
www.streetinsider.com - January 9 at 7:16 AM
Allergan Provides 2018 Preliminary Financial Outlook for Select Income Statement Categories and Other Updates at 36th Annual J. P. Morgan ConferenceAllergan Provides 2018 Preliminary Financial Outlook for Select Income Statement Categories and Other Updates at 36th Annual J. P. Morgan Conference
finance.yahoo.com - January 9 at 7:16 AM
After-hours buzz: AGN, URBN & moreAfter-hours buzz: AGN, URBN & more
finance.yahoo.com - January 9 at 7:16 AM
How Allergan Continues to Make Drug Prices InsaneHow Allergan Continues to Make Drug Prices Insane
finance.yahoo.com - January 9 at 7:16 AM
Allergan forecasts 2018 revenue below estimatesAllergan forecasts 2018 revenue below estimates
finance.yahoo.com - January 9 at 7:16 AM
Allergan CEO Saunders Says Stock Price Doesnt Reflect Companys True ValueAllergan CEO Saunders Says Stock Price Doesn't Reflect Company's True Value
finance.yahoo.com - January 9 at 7:16 AM
Allergan plc (AGN) Given Consensus Rating of "Hold" by AnalystsAllergan plc (AGN) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - January 9 at 5:58 AM
Allergan (AGN) Updates FY18 Earnings GuidanceAllergan (AGN) Updates FY18 Earnings Guidance
www.americanbankingnews.com - January 8 at 5:26 PM
Allergan to Report Fourth Quarter and Full Year 2017 Earnings and Host Conference Call and Webcast - PR Newswire (press release)Allergan to Report Fourth Quarter and Full Year 2017 Earnings and Host Conference Call and Webcast - PR Newswire (press release)
www.prnewswire.com - January 8 at 3:23 PM
Should Pfizer Make A Second Attempt To Acquire Allergan? - Seeking AlphaShould Pfizer Make A Second Attempt To Acquire Allergan? - Seeking Alpha
seekingalpha.com - January 8 at 3:23 PM
Allergan to Report Fourth Quarter and Full Year 2017 Earnings and Host Conference Call and WebcastAllergan to Report Fourth Quarter and Full Year 2017 Earnings and Host Conference Call and Webcast
finance.yahoo.com - January 8 at 10:56 AM
Royal Bank of Canada Reiterates "$218.00" Price Target for Allergan (AGN)Royal Bank of Canada Reiterates "$218.00" Price Target for Allergan (AGN)
www.americanbankingnews.com - January 7 at 12:44 AM
Allergan: 1000 Layoffs Prove Growth Is Dead - Seeking AlphaAllergan: 1000 Layoffs Prove Growth Is Dead - Seeking Alpha
seekingalpha.com - January 6 at 3:18 PM
Americas Opioid Crisis Looks A Lot Big Tobacco Spats of YesteryearAmerica's Opioid Crisis Looks A Lot Big Tobacco Spats of Yesteryear
finance.yahoo.com - January 6 at 7:49 AM
PFF, AGN, HSBC, DB: ETF Outflow Alert - NasdaqPFF, AGN, HSBC, DB: ETF Outflow Alert - Nasdaq
www.nasdaq.com - January 5 at 3:51 PM
Has Allergan Declined Enough To Be Attractive? - Seeking AlphaHas Allergan Declined Enough To Be Attractive? - Seeking Alpha
seekingalpha.com - January 5 at 3:51 PM
Edited Transcript of AGN earnings conference call or presentation 5-Aug-14 12:30pm GMTEdited Transcript of AGN earnings conference call or presentation 5-Aug-14 12:30pm GMT
finance.yahoo.com - January 5 at 3:20 PM

SEC Filings

Allergan (NYSE:AGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Allergan (NYSE:AGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Allergan (NYSE AGN) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.